A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2018
Price : $35 *
At a glance
- Drugs Hydroxychloroquine (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 20 Aug 2018 Status changed from active, no longer recruiting to completed.
- 22 Jan 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jan 2016, as reported by ClinicalTrials.gov.